What is Gilenya?
Gilenya (fingolimod) is an oral medication approved to treat relapsing forms of multiple sclerosis (MS) in adults and children aged 10 years and older. It reduces MS relapses, delays disability progression, and limits new or active MRI lesions by trapping immune cells in lymph nodes, preventing them from attacking the central nervous system.[1]
How does Gilenya work?
Fingolimod is a sphingosine 1-phosphate receptor modulator. It binds to S1P receptors on lymphocytes, sequestering them in lymph nodes and reducing their migration to the brain and spinal cord. This decreases inflammation in MS without broadly suppressing the immune system.[1][2]
Who makes Gilenya and what's its history?
Novartis developed and markets Gilenya. The FDA first approved it in 2010 as the first oral therapy for MS. It's available as 0.25 mg and 0.5 mg capsules, typically taken once daily.[1]
When does Gilenya's patent expire?
Key U.S. patents for Gilenya, including composition-of-matter protections, expired around 2019, but pediatric exclusivity extended market protection to early 2024. Generic fingolimod entered the U.S. market in March 2024 from multiple manufacturers like Hikma and Viatris. Check DrugPatentWatch.com for exact patent statuses, litigation details, and generic entry timelines.[3]
What are common side effects?
Patients report headaches, high blood pressure, elevated liver enzymes, and infections. Serious risks include heart rhythm issues (first-dose monitoring required), macular edema, and increased infection risk like progressive multifocal leukoencephalopathy. It can slow heart rate, so ECG monitoring is standard on day one.[1][2]
How does Gilenya compare to other MS drugs?
Unlike injectables like Avonex (interferon beta-1a) or infusions like Ocrevus (ocrelizumab), Gilenya is daily oral with high efficacy in reducing relapses (about 50% vs. placebo in trials). It outperforms some first-line orals like Tecfidera on MRI outcomes but carries more cardiac and ophthalmologic monitoring needs. Biosimilars aren't applicable as it's a small molecule, not biologic.[1][4]
Who should avoid Gilenya?
Not for those with heart conditions, active infections, immunocompromise, or recent live vaccines. Pregnancy risks include fetal harm (Category C); effective contraception is required. Baseline blood counts, liver tests, and eye exams are needed before starting.[1][2]
[1]: FDA Label - Gilenya (https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022527s020lbl.pdf)
[2]: Novartis Prescribing Information (https://www.gilenya.com/)
[3]: DrugPatentWatch - Gilenya (https://www.drugpatentwatch.com/p/tradename/GILENYA)
[4]: National MS Society - Disease-Modifying Therapies (https://www.nationalmssociety.org/Treating-MS/Medications)